Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019008605) NOVEL PHARMACEUTICAL CO-CRYSTAL OF DABIGATRAN ETEXILATE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/008605 International Application No.: PCT/IN2018/050444
Publication Date: 10.01.2019 International Filing Date: 07.07.2018
IPC:
A61K 31/167 (2006.01) ,A61K 31/198 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
16
Amides, e.g. hydroxamic acids
165
having aromatic rings, e.g. colchicine, atenolol, progabide
167
having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
195
having an amino group
197
the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198
Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
Applicants:
ZIM LABORATORIES LIMITED [IN/IN]; Ground Floor, Sadoday Gyan, Nelson Square, Chhindwara Road, Nagpur, Maharashtra 440 013, IN
Inventors:
DAUD, Anwar Siraj; IN
POL, Shankar Dadasaheb; IN
NAWALE, Rajesh Bhaskar; IN
PURANIK, Prashant Keshao; IN
MATHUR, Vijay Bhagwanswarup; IN
JAMALUDDIN, Shamsuddin; IN
RAJKONDAWAR, Vishal Vasant; IN
Agent:
SINGH, Manisha; IN
Priority Data:
20172102407807.07.2017IN
Title (EN) NOVEL PHARMACEUTICAL CO-CRYSTAL OF DABIGATRAN ETEXILATE
(FR) NOUVEAU CO-CRISTAL PHARMACEUTIQUE D'ÉTÉXILATE DE DABIGATRAN
Abstract:
(EN) The present invention discloses novel co-crystals of dabigatran etexilate or its pharmaceutically acceptable salts. The novel co-crystals of dabigatran etexilate or its pharmaceutically acceptable salts are prepared using an amino acid as a co-former, preferably, with leucine. The present invention also provides formulation comprising novel co-crystals of dabigatran etexilate or its pharmaceutically acceptable salts.
(FR) La présente invention concerne de nouveaux co-cristaux d'étéxilate de dabigatran ou de ses sels pharmaceutiquement acceptables. Les nouveaux co-cristaux d'étéxilate de dabigatran ou de ses sels pharmaceutiquement acceptables sont préparés à l'aide d'un acide aminé en tant que co-formeur, de préférence, avec de la leucine. La présente invention concerne également une formulation comprenant de nouveaux co-cristaux d'étéxilate de dabigatran ou de ses sels pharmaceutiquement acceptables.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)